Clinical Report: Real-World Data Supports Uveal Melanoma Test Combo
Overview
New data from the 2025 ARVO meeting confirms that combining PRAME status with the DecisionDx-UM test significantly enhances metastatic risk stratification in uveal melanoma. This independent validation of previous studies demonstrates improved prognostic accuracy for patient outcomes.
Background
Uveal melanoma is a rare but aggressive form of eye cancer, and accurate risk stratification is crucial for patient management. The DecisionDx-UM test, which classifies tumors based on gene expression, is widely utilized in clinical practice. Integrating additional biomarkers like PRAME can refine predictions of metastasis, ultimately guiding treatment decisions.
Data Highlights
| Class | PRAME Status | 3-Year Survival Rate |
|---|---|---|
| Class 1 | Negative | 98.3% |
| Class 1 | Positive | 91.7% |
| Class 2 | Negative | 87.9% |
| Class 2 | Positive | 66.7% |
Key Findings
- The combination of PRAME status and DecisionDx-UM enhances metastatic risk stratification.
- Three-year melanoma-specific survival rates vary significantly based on PRAME status within each tumor class.
- Patients with Class 2/PRAME-positive tumors have a hazard ratio of 25.3 for melanoma-specific death compared to Class 1/PRAME-negative tumors.
- The study analyzed data from 1,297 patients, marking the first independent validation of the COOG2.1 study.
- DecisionDx-UM is recommended by NCCN guidelines and is used by nearly 80% of newly diagnosed uveal melanoma patients in the U.S.
Clinical Implications
The integration of PRAME status into the DecisionDx-UM test can significantly improve the accuracy of metastatic risk assessments in uveal melanoma patients. Clinicians should consider this combined approach to enhance prognostication and tailor follow-up strategies accordingly.
Conclusion
The findings from the 2025 ARVO meeting reinforce the value of combining PRAME with the DecisionDx-UM test for improved risk stratification in uveal melanoma, supporting better clinical decision-making.
References
- The ASCO Post, Clinical Trials Actively Recruiting Patients With Ocular Cancer, 2016 -- Clinical Trials Actively Recruiting Patients With Ocular Cancer
- Retinal Physician, New Treatments for Ocular Melanoma, 2023 -- New Treatments for Ocular Melanoma
- The ASCO Post, ASCO Guideline Update for Systemic Melanoma Therapy Addresses New Treatment Option for Uveal Melanoma, 2022 -- ASCO Guideline Update for Systemic Melanoma Therapy Addresses New Treatment Option for Uveal Melanoma
- Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up, 2026 -- ESMO–EURACAN Clinical Practice Guideline
- 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma, 2023 -- First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)
- the ophthalmologist — Modeling the Genetics of Uveal Melanoma
- Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up - ScienceDirect
- 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) - PMC
- State-of-the-art in Metastatic Uveal Melanoma Treatment: A 2025 Update | Current Oncology Reports | Springer Nature Link
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.